(Q37724396)

22 August 2017

1 reference

title

The future of CD20 monoclonal antibody therapy in B-cell malignancies (English)

1 reference

22 August 2017

1 reference

1 reference

Myron S Czuczman

1

1 reference

22 August 2017

Stephanie A Gregory

series ordinal

2

1 reference

22 August 2017

publication date

1 June 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

51

1 reference

22 August 2017

issue

6

1 reference

22 August 2017

page(s)

983-994

1 reference

Lymphoma: diagnosis, staging, natural history, and treatment strategies

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Follicular lymphoma international prognostic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Mechanisms of killing by anti-CD20 monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Anti-CD20-based therapy of B cell lymphoma: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Selective internalization of monoclonal antibodies by B‐cell chronic lymphocytic leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

CD20: a regulator of cell-cycle progression of B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

The biology of CD20 and its potential as a target for mAb therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Complement activation determines the therapeutic activity of rituximab in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Monoclonal antibodies for B-cell lymphomas: rituximab and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Rituximab dose-escalation trial in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Maintenance therapy for low-grade lymphomas: has the time come?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428191003717746

10.3109/10428191003717746

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference